Oxford BioMedica

Deutsche Bank has downgraded Oxford BioMedica from "buy" to "hold" and cut its scenario-based price target from 800 pence to 595 pence. The reasons are a slower conversion of demand into reported revenues, delays in programs and operational issues at the Durham site. The bank reduced its revenue estimates for 2026 and 2027 by about 20%, which weighs more heavily on profit and EBITDA. Deutsche Bank now places the onus of proof on execution and views the capital markets day as an important test for management. » Mere på de.investing.com

Oxford BioMedica has reduced its 2026 revenue forecast to £180–200 million from £220–240 million previously. The stock fell about 18% to an intraday low and is trading near its 52-week low after management cited short-term changes in customer ordering behavior as the reason. The forecast revision deals a heavy blow to the recently confirmed targets and has led to a marked loss of investor confidence. » Mere på de.investing.com

Two executives of Oxford Biomedica, Natalie Walter and Lisa Doman, exercised stock options and subsequently sold shares on the London Stock Exchange. Walter exercised 3,057 options under the Save As You Earn scheme at £2.944 and disposed of the shares at an average of £6.3939 (proceeds approx. £19,546). Doman exercised 10,591 options from the Deferred Bonus Plan free of charge and 2,709 options from the Executive Share Option Scheme at £4.966, and sold a total of 13,300 shares at an average of £6.35 (volume approx. £84,455). The transactions were disclosed in accordance with the EU Market Abuse Regulation. » Mere på de.investing.com